NLRC4 and macrophage activation syndrome: To support this view, administration of IL-18BP, the IL-18-blocking molecule, markedly relieved MAS-like symptoms in a patient with confirmed de novo mutation in the NLRC4 gene with concomitant IL-18 serum level elevation [56].